What is the 13F Pro Quality Score for BCTX?

13F Pro ranks BriaCell Therapeutics Corp. (BCTX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BCTX's current score at https://13fpro.ai/research/BCTX (free sign-up required for the full ranking).

Which hedge funds own the most BCTX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of BCTX include Cable Car Capital,, SABBY MANAGEMENT,, IRIDIAN ASSET MANAGEMENT /CT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/BCTX as soon as new 13F filings post.

Where does 13F Pro source BCTX data?

All BriaCell Therapeutics Corp. fundamentals and ownership data come directly from SEC EDGAR. BriaCell Therapeutics Corp. files with the SEC under CIK 1610820. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BCTX in?

BriaCell Therapeutics Corp. (BCTX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is BCTX research updated on 13F Pro?

BCTX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

BriaCell Therapeutics Corp.(BCTX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1610820 BCTX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

BCTX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for BriaCell Therapeutics Corp. (BCTX), a Healthcare sector company. BCTX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q3 2026), BriaCell Therapeutics Corp. reports net income of $-7.2M, free cash flow of $-7.0M. Top institutional holders of BCTX by reported 13-F value include Cable Car Capital,, SABBY MANAGEMENT,, IRIDIAN ASSET MANAGEMENT /CT, based on the most recent SEC filings. BCTX trades on the Nasdaq exchange and files with the SEC under CIK 1610820. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BCTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BriaCell Therapeutics Corp. directly from SEC EDGAR.

Net Income

Q3 2026

$-7.2M

Free Cash Flow

Q3 2026

$-7.0M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-449.1% YoY

$-26.3MFY 2025

FY22 $-26.8MFY23 $-20.3MFY24 $-4.8MFY25 $-26.3M

Operating Income

+18.4% YoY

$-27.2MFY 2025

FY22 $-15.3MFY23 $-23.3MFY24 $-33.3MFY25 $-27.2M

EPS (Diluted)

-42.4% YoY

$-62.19FY 2025

FY22 $-1.73FY23 $-1.30FY24 $-43.68FY25 $-62.19

Total Assets

+268.7% YoY

$21.6MFY 2025

FY22 $42.6MFY23 $27.2MFY24 $5.9MFY25 $21.6M

Op. Cash Flow

-16.8% YoY

$-28.2MFY 2025

FY22 $-12.5MFY23 $-23.7MFY24 $-24.1MFY25 $-28.2M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Income	$-26.3M -449.1%	$-4.8M +76.4%	$-20.3M +24.4%	$-26.8M -94.3%	$-13.8M
Operating Income	$-27.2M +18.4%	$-33.3M -43.2%	$-23.3M -52.2%	$-15.3M -119.2%	$-7.0M
EPS (Diluted)	$-62.19 -42.4%	$-43.68 -3260.0%	$-1.30 +24.9%	$-1.73	—
Total Assets	$21.6M +268.7%	$5.9M -78.4%	$27.2M -36.2%	$42.6M -26.6%	$58.0M
Operating Cash Flow	$-28.2M -16.8%	$-24.1M -1.6%	$-23.7M -90.2%	$-12.5M -61.1%	$-7.8M

AI Insight: BCTX Financial Trends

BCTX remains pre-revenue with consistently negative operating cash flow; burn rate stabilized around $7–8M quarterly but shows no path to profitability.

• Net income loss widened from $1M in Q3 2024 to $8M by Q3–Q4 2025, then moderated to $7M in Q1–Q2 2026.

• Operating cash flow deteriorated from $4M negative in Q3 2024 to $8M negative in Q3 2025, holding steady at $7–8M through Q2 2026.

⚠ No revenue reported across all eight quarters; clinical-stage company burning cash with no near-term commercialization signal visible.

⚠ Operating margin and debt/equity metrics unavailable; equity position and runway duration cannot be assessed from provided data.

AI Insight: BCTX Ratio Trends

Data too sparse to establish meaningful trends; only ROA visible, showing persistent deep losses with minimal improvement.

• ROA deteriorated from -82.7% in Q3 2024 to -86.0% in Q1 2026, signaling worsening asset efficiency amid ongoing losses.

⚠ Operating margin, NPM, ROE, ROIC, and leverage ratios absent across all periods; unable to assess profitability trajectory or capital structure.

⚠ Sustained negative ROA indicates company remains pre-revenue or unprofitable; critical to monitor cash burn and runway.

Get alerted when BCTX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for BriaCell Therapeutics Corp. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BCTX

Cable Car Capital, LP
$908.5K216,821 sh
SABBY MANAGEMENT, LLC
$309.7K73,915 sh
IRIDIAN ASSET MANAGEMENT LLC/CT
$272.4K65,000 sh
Empery Asset Management, LP
$93.3K666,600 sh
HEIGHTS CAPITAL MANAGEMENT, INC
$75.6K540,098 sh
LuminArx Capital Management LP
$62.9K15,000 sh
UBS Group AG
$48.4K11,541 sh
SABBY MANAGEMENT, LLC
$28.9K206,753 sh
MORGAN STANLEY
$12.7K3,021 sh
NATIONAL BANK OF CANADA /FI/
$2.6K802 sh

Fund	Value	Shares
Cable Car Capital, LP	$908.5K	216,821
SABBY MANAGEMENT, LLC	$309.7K	73,915
IRIDIAN ASSET MANAGEMENT LLC/CT	$272.4K	65,000
Empery Asset Management, LP	$93.3K	666,600
HEIGHTS CAPITAL MANAGEMENT, INC	$75.6K	540,098
LuminArx Capital Management LP	$62.9K	15,000
UBS Group AG	$48.4K	11,541
SABBY MANAGEMENT, LLC	$28.9K	206,753
MORGAN STANLEY	$12.7K	3,021
NATIONAL BANK OF CANADA /FI/	$2.6K	802

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put BCTX on your watchlist

Track score changes the day BriaCell Therapeutics Corp. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BCTX a good stock to buy?

13F Pro's AI-powered analysis of BriaCell Therapeutics Corp. (BCTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BCTX are available on the BCTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own BCTX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BCTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BriaCell Therapeutics Corp.'s investment landscape.